German drug and chemical maker Merck says it plans to shut the Swiss headquarters of its Merck Serono pharmaceutical division, cutting more than 500 jobs.
This content was published on
2 minutes
swissinfo.ch and agencies
Merck said on Tuesday in a statement that it plans to transfer more than 750 of the 1,250 positions at Serono’s Geneva headquarters to other Merck sites. It said it expects to cut the other 500 jobs in Geneva and another 80 at Swiss manufacturing sites “to create a leaner, more agile organization.”
The move is part of a wider efficiency program that Merck, based in Darmstadt, Germany, launched in February.
The company said that, after consulting with employees, it aims to start implementing the relocations and job cuts in Switzerland in the second half of this year. Research and development positions will be moved to Germany, Boston and Beijing.
The Geneva authorities were told of Merck’s plans on Monday and the employees were informed on Tuesday morning. The cantonal government is not planning to offer tax breaks to encourage Merck to reverse its decision.
Merck said that production units in Aubonne, Corsier-sur-Vevey and Coinsins in canton Vaud would be maintained although around 80 positions would be lost. More than 130 technical specialists from Geneva will also be transferred to those sites.
The German firm added that its Swiss commercial operations based in Zug were not affected by the job cuts.
Merck bought Serono from the Bertarelli family in 2006 for SFr16 billion ($17.5 billion). Last year, it generated €5.6 billion (SFr6.7 billion), or 60 per cent of Merck’s turnover.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis U-turn is a “win-win solution”
This content was published on
Described at the time by the pharmaceutical giant as a pre-emptive move, the announcement of 1,080 Swiss job cuts, alongside news of multi-billion profit figures, caused consternation in Switzerland. “We’re facing an increasingly difficult environment which is likely to get even tougher over the next five years,” Novartis CEO Joe Jimenez said in October, commenting…
This content was published on
The Bertarelli family reportedly dropped negotiations with other suitors when Serono was up for sale earlier this year before deciding to sell its majority 64.5 per cent stake on Thursday. The ailing company hired Goldman Sachs to find a buyer last December only to announce surprisingly four months later that it was looking to expand…
This content was published on
The deal values the Swiss firm at SFr16.1 billion ($12.9 billion) and gives Merck 75.5 per cent of voting rights in Serono. The new company will be called Merck-Serono and will continue to have its headquarters in Geneva. The United States base will remain in Boston. Based on 2005 figures, the new company will have…
This content was published on
It all began with the textile industry, which made use of charming products such as sulphuric acid and caustic soda. In Switzerland attention soon turned to dyes, then medicines, herbicides, insecticides and fragrances.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.